Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090443 | 0.85 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL17596207 | 0.78 | MAP4K4 (0.37) | MAP4K4GPR119MEN1KMT2ASETD7 | |
| SCHEMBL17596209 | 0.78 | MAP4K4 (0.37) | MAP4K4GPR119MEN1KMT2ASETD7 | |
| SCHEMBL2753515 | 0.77 | NR1H2 (0.40) | MEN1KMT2A | |
| SCHEMBL26089938 | 0.75 | MAP4K4 (0.35) | MAP4K4GPR119MEN1KMT2ASETD7 | |
| SCHEMBL26093734 | 0.74 | GRM5 (0.36) | MAP4K4GPR119MEN1KMT2ASETD7 | |
| SCHEMBL26429541 | 0.71 | CTSK (0.43) | MAP4K4KMT2ASUV39H2HSD11B1 | |
| SCHEMBL34469080 | 0.70 | GPR119 (0.38) | MAP4K4GPR119MEN1KMT2ASETD7 | |
| SCHEMBL344752 | 0.69 | TSHR (0.56) | MAP4K4GPR119SETD7 | |
| SCHEMBL527701 | 0.69 | TSHR (0.56) | MAP4K4GPR119SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | MAP4K4 2519/4885GPR119 3532/4885MEN1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.